The short version of trans-3-hexenoyl fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Nucleosides are molecules formed by attaching a nucleobase to a ribose or deoxyribose ring. Examples of these include cytidine (C), uridine (U), adenosine (A), guanosine (G), and thymidine (T). Nucleosides can be phosphorylated by specific kinases in the cell, producing nucleotides. Both DNA and RNA are polymers, consisting of long, linear molecules assembled by polymerase enzymes from repeating structural units, or monomers, of mononucleotides. DNA uses the deoxynucleotides C, G, A, and T, while RNA uses the ribonucleotides (which have an extra hydroxyl(OH) group on the pentose ring) C, G, A, and U. Modified bases are fairly common (such as with methyl groups on the base ring), as found in ribosomal RNA or transfer RNAs or for discriminating the new from old strands of DNA after replication. Each nucleotide is made of an acyclic nitrogenous base, a pentose and one to three phosphate groups. They contain carbon, nitrogen, oxygen, hydrogen and phosphorus. They serve as sources of chemical energy (adenosine triphosphate and guanosine triphosphate), participate in cellular signaling (cyclic guanosine monophosphate and cyclic adenosine monophosphate), and are incorporated into important cofactors of enzymatic reactions (coenzyme A, flavin adenine dinucleotide, flavin mononucleotide, and nicotinamide adenine dinucleotide phosphate).
Levorphanol's exceptionally high analgesic efficacy in the treatment of neuropathic pain is also conferred by its action on serotonin and norepinephrine transporters, similar to the opioids tramadol and tapentadol, and mutually complements the analgesic effect of its NMDA receptor antagonism. Levorphanol shows a high rate of psychotomimetic side effects such as hallucinations and delirium, which have been attributed to its binding to and activation of the KOR. At the same time however, activation of this receptor as well as of the DOR have been determined to contribute to its analgesic effects.
=== Role in fetal development === CRH is not found in the oocytes of primordial follicles in normal human ovaries. However, there is a significant amount of CRH and its CRH-R1 gene expression in mature follicles . This suggests that CRH has auto/paracrine functions in the maturation of follicles. The level of CRH is greater in the ovaries of premenopausal women compared to postmenopausal women, indicating that ovarian CRH is associated with normal ovarian function throughout the reproductive lifespan.
Retinal dystrophy (cone-rod dystrophy) in all cases, usually within a few weeks of birth and progressively worsening until about 20 years of age when vision is lost. Nystagmus (often one of the first symptoms identified) and photophobia are also very common. Mild to moderate progressive bilateral sensorineural hearing loss. Hearing impairment is typically diagnosed between the ages of 1 and 10. Congestive heart failure (dilated cardiomyopathy) in over 60% of individuals over the course of their lifetimes. Around 40% of individuals suffer from a severe cardiomyopathy within the first few months of life. For those who survive, cardiomyopathy occurs in 1 of 5 patients with onset in adolescence or adulthood. Hypothyroidism tends to occur in less than half of patients. Growth hormone dysfunction is common in around half of individuals with AS. Thoracic and lumbar scoliosis, kyphosis, or lordosis is present in around 68% of patients. Male hypergonadotropic and hypogonadotropic hypogonadism and female hyperandrogenism. Men can experience microphallus, undescended testes, hypospadias, small testes, and gynecomastia. They are also unlikely to be fertile. Women can experience hirsutism, alopecia, oligomenorrhea/amenorrhea, polycystic ovaries, high testosterone levels, abnormal breast development, precocious puberty, and endometriosis. Female fertility is unlikely and only reported in a few cases. Childhood obesity occurs in most people with AS. Alström infants are usually within the normal birth weight and then experience rapid weight gain within the first 2–36 months.
== Chiral chromatography == This term has become very popular and commonly used in practice. But the appropriate expression is "enantioselective chromatography". Chiral chromatography has advanced to turn into the most preferred technique for the determination of enantiomeric purity as well as separation of pure enantiomers both on analytical and preparative scale. Chiral chromatographic assay is the first step in any study pertaining to enantioselective synthesis or separation. This includes the use of techniques viz. gas chromatography (GC), high performance liquid chromatography (HPLC), chiral supercritical fluid chromatography (SFC), capillary electrophoresis (CE) and thin-layer chromatography (TLC). The result of a literature survey done identifies HPLC-based chiral assays as the most dominating technology in use. An overview of various analytical methods engaged for chiral separation and analysis are listed in the table.
Sources: en.wikipedia.org
=== Engineered peptidyl transferase center === In 2014, it was shown that by altering the peptidyl transferase center of the 23S rRNA, ribosomes could be created which draw on orthogonal pools of tRNA. The 3' end of tRNAs is universally conserved to be CCA. The two cytidines base pair with two guanines the 23S rRNA to bind the tRNA to the ribosome. This interaction is required for translational fidelity. However, by co-mutating the binding nucleotides in such a way, that they can still base pair, the translational fidelity can be conserved. The 3'-end of the tRNA is mutated from CCA to CGA, while two cytidine nucleotides in the ribosomes A- and P-sites are mutated to guanidine. This leads to ribosomes which do not accept naturally occurring tRNAs as substrates and to tRNAs, which cannot be used as substrate by natural ribosomes. To use such tRNAs effectively, they would have to be aminoacylated by specific, orthogonal aaRSs. Most naturally occurring aaRSs recognize the 3'-end of their corresponding tRNA. aaRSs for these 3'-mutated tRNAs are not available yet. Thus far, this system has only been shown to work in an in-vitro translation setting where the aminoacylation of the orthogonal tRNA was achieved using so called "flexizymes". Pioneered by the laboratory of Hiroaki Suga at the University of Tokyo, flexizymes are ribozymes with tRNA-amino-aclylation activity.
, the surface behaves elastically during contact. In both the Greenwood-Williamson and Mikic models the load is assumed to be proportional to the deformed area. Hence, whether the system behaves plastically or elastically is independent of the applied normal force.
=== Neurotransmission === Inhibitory neurons in the central nervous system play a homeostatic role in the balance of neuronal activity between excitation and inhibition. Inhibitory neurons using GABA, make compensating changes in the neuronal networks preventing runaway levels of excitation. An imbalance between excitation and inhibition is seen to be implicated in a number of neuropsychiatric disorders.
=== August === 1 August – Stella Maris, the Rector of the University of St Andrews, is removed from the university's governing body over a letter she sent to students shortly after taking office in which she called for an immediate ceasefire in Gaza and referred to "genocidal attacks" made by the Israeli government. She will remain as Rector until October 2026, when her term ends. 4 August – A yellow weather warning is issued for heavy rain and strong winds in parts of Scotland, which is active until 9pm the following day. 6 August – Fiona Robertson, the chief executive of the Scottish Qualifications Authority, apologises after around 7,000 students who took their Higher examinations received blank emails instead of their results. The results were later sent by text message. 8 August – Cosla puts forward a new offer of a 3.6% increase for all grades of refuse workers in a bid to prevent strikes in 26 of Scotland's 32 council areas. The offer would represent a rise of £1,292 for the lowest paid, equivalent to a 5.63% increase. 8–12 August – The 82nd World Science Fiction Convention takes place in Glasgow. 9 August – 2024 United Kingdom riots: Police Scotland announces it is sending 120 of their officers to Belfast to help deal with ongoing riots in the city. 12 August – Unison, Unite and the GMB suspend planned strikes by refuse collectors following a new offer from Cosla. 13 August – Scotland's gender service for young people, based in Glasgow, announces it will stop accepting self-referrals.
Sources: en.wikipedia.org
== Distribution == Psilocybe authority Gastón Guzmán, in his 1983 monograph on psilocybin mushrooms, considered Psilocybe semilanceata the world's most widespread psilocybin mushroom species, as it has been reported on 18 countries. In Europe, P. semilanceata has a widespread distribution, and is found in Austria, Belarus, Belgium, Bulgaria, the Channel Islands, Czech republic, Denmark, Estonia, the Faroe Islands, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, India, Ireland, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, the United Kingdom and Ukraine. It is generally agreed that the species is native to Europe; Watling has demonstrated that there exists little difference between specimens collected from Spain and Scotland, at both the morphological and genetic level. The mushroom also has a widespread distribution in North America. In Canada it has been collected from British Columbia, New Brunswick, Newfoundland, Nova Scotia, Prince Edward Island, Ontario and Quebec. In the United States, it is most common in the Pacific Northwest, west of the Cascade Mountains, where it fruits abundantly in autumn and early winter; fruiting has also been reported to occur infrequently during spring months. Charles Horton Peck reported the mushroom to occur in New York in the early 20th century, and consequently, much literature published since then has reported the species to be present in the eastern United States.
Xi and CCP ideologues coined the phrase "Chinese Dream" to describe his overarching plans for China as its leader. Xi first used the phrase during a high-profile visit to the National Museum of China on 29 November 2012, where he and his Politburo Standing Committee colleagues were attending a "national revival" exhibition. Since then, the phrase has become the signature political slogan of the Xi era. The origin of the term "Chinese Dream" is unclear. While the phrase has been used before by journalists and scholars, some publications have posited the term likely drew its inspiration from the concept of the American Dream. The Economist noted the abstract and seemingly accessible nature of the concept with no specific overarching policy stipulations may be a deliberate departure from the jargon-heavy ideologies of his predecessors. Xi has linked the "Chinese Dream" with the phrase "great rejuvenation of the Chinese nation".
=== Applications in Infectious diseases === One way to detect these pathogens is detect part of their genome by metagenomics sequencing (Next Generation Sequencing-mNGS), which can be targeted or untargeted.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.